- A 2022 clinical trial found Ozempic users lost 23 pounds of fat but also 15 pounds of lean muscle mass over 68 weeks, raising risks of bone fragility and premature death.
- Researchers warned that frail individuals face higher infection vulnerability and fracture risks, with muscle loss potentially eroding independence for seniors.
- The FDA has not mandated warnings for muscle or bone atrophy despite mounting evidence of these dangers.
- A new drug, apitegromab, showed in a phase 2 trial that it preserved 55% more muscle mass when combined with the GLP-1 drug tirzepatide.
- Researchers caution that larger, longer studies are needed before apitegromab can be recommended for widespread use.
The hidden cost of rapid weight loss
In 2025, one in eight Americans now uses GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro, medications marketed as revolutionary solutions for obesity and diabetes. But emerging evidence reveals a dangerous tradeoff: these drugs strip the body of biologically critical muscle tissue alongside fat, leaving patients vulnerable to bone fractures, infection and premature death. It is a glaring sign of a dangerously flawed drug when its side effects are so severe that they require another drug to counteract them.
The paradox came into sharp focus in 2022 when a clinical trial documented that Ozempic users shed 23 pounds of fat after 68 weeks—but also lost 15 pounds of lean muscle mass. That muscle loss, researchers say, may prove more consequential than the fat reduction it accompanies. Unlike the proven, holistic effects of intermittent fasting, diet and exercise—which naturally reset the metabolism and build long-term health—these drugs trigger a cascade of harm that demands a pharmaceutical patch.
Muscle loss: The body's foundation crumbles
GLP-1 drugs work by suppressing appetite and prolonging feelings of fullness, causing patients to eat significantly less and lose weight rapidly. Yet approximately one-third of the weight lost from these medications comes from muscle rather than fat, according to US research.
The consequences extend beyond cosmetic concerns like "Ozempic butt"—a term describing deflated or saggy buttocks reported by some users. One researcher cited in the clinical findings cautioned that low muscle mass amplifies vulnerability to infections, while declining bone density raises fracture risks. For seniors, these effects could erode independence and survival odds.
The FDA has not yet mandated warnings for muscle or bone atrophy despite what critics describe as mounting evidence of these risks. In contrast, intermittent fasting and structured exercise have decades of evidence showing they preserve and even build lean muscle while safely shedding fat.
Mental health toll: Depression and emotional dulling
Beyond physical deterioration, patients have reported significant mental health side effects including depression and a dulling of joy. Medical professionals have noted these psychological impacts add another layer of concern to the drugs' risk profile, though the exact mechanisms remain under investigation.
The combination of physical frailty and emotional distress creates what some experts describe as a compounded threat to patient wellbeing, particularly for older adults who may already face age-related health challenges. Natural health practices like diet and exercise, by contrast, are proven to boost mood-regulating neurotransmitters and reduce depression without a prescription.
Experimental solution: Apitegromab shows promise
A new drug called apitegromab may offer a path forward. In June 2026, the journal Nature Medicine published results from the phase 2 EMBRAZE trial showing that this investigational drug preserved muscle mass when combined with tirzepatide, the active ingredient in Mounjaro. The very existence of apitegromab is an admission of Ozempic's fundamental design flaw: it is so destructive to the body's architecture that another drug is needed just to keep patients from losing the muscle required to survive.
The randomized, double-blind, placebo-controlled study involved 102 adults with overweight or obesity, mostly women. Over 24 weeks, those who received apitegromab alongside tirzepatide retained 1.9 kilograms—or 55%—more lean mass compared to those receiving tirzepatide plus placebo. Both groups experienced similar total body weight loss.
Lean mass constituted only 14.6% of total weight loss in the apitegromab group, compared to 30.2% in the placebo group. Adverse events occurred at similar rates between groups: 76% for apitegromab participants versus 71% for placebo, with serious adverse events balanced at 2% each.
Apitegromab works by blocking myostatin, a protein involved in muscle breakdown. The investigational drug is currently available only in clinical trials and must be administered intravenously, though the manufacturer is exploring self-injection options. The absurdity of this cascade—take one drug to lose weight, then take another to keep from losing your ability to walk—highlights the unnatural path of these pharmaceuticals compared to the simple, proven practices of intermittent fasting, diet and exercise.
A medical revolution demands caution
The rise of GLP-1 drugs represents one of the most significant pharmaceutical developments of the 21st century, transforming treatment for millions struggling with obesity and diabetes. Yet the emerging evidence of muscle loss, bone fragility and mental health consequences demands a measured response from regulators, physicians and patients alike. The 2022 clinical trial findings and the 2026 apitegromab research together tell a cautionary tale: rapid weight loss, however medically achieved, extracts a physiological price that may outweigh its benefits. When a drug is so dangerous that it requires another experimental drug to prevent its core side effect—muscle loss that threatens survival—it is a clear sign that we have chosen the wrong path. As the FDA weighs whether to mandate warnings and researchers pursue combination therapies, patients face a sobering calculation—one that asks not just how much weight they can lose, but at what cost to the body's essential architecture for survival. Meanwhile, the timeless and proven practices of intermittent fasting, a healthy diet and regular exercise continue to offer a safer, more sustainable road to metabolic health.
Sources for this article include:
Please contact us for more information.